Merck's Gardasil 9 launches in Canada; Immunomic wins NIH grant for peanut allergy candidate;

> Merck's ($MRK) Gardasil 9 has launched in Canada. Release

> Immunomic Therapeutics has won a Small Business Innovation Research grant from the NIH for its work on a peanut allergy vaccine. Release

> Diabetes vaccine maker Diamyd Medical has received 15 million Swedish krona ($1.7 million) in a direct issue. Release

> The human vaccine market in China is slated to jump as R&D and production capacity grow. Release

And Finally... Geovax has assigned a trial number to the next study of its candidate HIV preventive. Release

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.